DoD Awards Ology Bioservices $135M in Medical Countermeasure Dev’t Contracts

Ology Bioservices has secured a pair of contracts worth $135.4M combined from the Department of Defense to develop a medical countermeasure against biological threats and a technology platform for producing nucleic acids.

The Alachua, Fla.-based biopharmaceutical company said Monday it will explore the use of monoclonal antibodies as a potential treatment for Yersinia pestis, the bacterium that causes plague, under a contract valued at $130.3M over 10 years.

Team members for the project are the Duke Human Vaccine Institute, Battelle, Just Biotherapeutics, Mapp Biopharmaceutical, Cato Research, Certara and the U.S. Army Medical Research Institute of Infectious Diseases.

Under the second contract, valued at $5.1M, Ology Bioservices will create a manufacturing technology prototype to produce plasmid DNA for potential use in genetic vaccines and gene therapy.

The 30-month agreement contains options for the company to facilitate the development of RNA manufacturing platforms.

DoD’s Platforms for Rapid Integrated Solutions for Medical Countermeasures office awarded the two contracts.

Check Also

telehealth

VA Seeks RPA-Based Software to Help Manage EHR Backlog

The Department of Veterans Affairs is conducting market research on commercially available robotic process automation technologies that can help streamline clinical document processing functions for electronic health records systems.

Anthony Cristillo SVP MSC

Anthony Cristillo Named Health Info Systems SVP at Dovel’s MSC Subsidiary

Anthony Cristillo, a more than 25-year biomedical research professional, has joined Dovel TechnologiesMedical Science & Computing subsidiary as senior vice president of health information systems.